Eucrisa (crisaborole) / Pfizer - LARVOL DELTA

Heterozygous Variants of the SLC39A4 Gene and Possible Increased Risk for Developing Acrodermatitis Enteropathica with Kaposi's Varicelliform Eruption. (PubMed, Am J Case Rep) - "The patient received oral zinc gluconate and topical crisaborole ointment, achieving complete resolution within 2 weeks...Genetic confirmation remains essential in atypical presentations. These novel variants broaden the mutational spectrum of SLC39A4 and emphasize the importance of early zinc supplementation and antiviral prophylaxis in patients with AE who display KVE risk."

Journal • Alopecia • Dermatitis • Dermatology • Immunology

Flow Process for Production of Crisaborole Using Organolithium Chemistry with Control over Impurity Formation. (PubMed, ACS Omega) - "This approach allowed for effective control over product formation, optimized conditions for scalability, and careful management of the three impurities. The application of a quality by design (QbD) approach in the flow synthesis of crisaborole enabled systematic control and minimization of three critical impurities by establishing a thorough understanding of process parameters and their impact on product quality while also ensuring optimized conditions for scalability and effective control over product formation."

Journal • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Layer-Resolved Biophysical Effects of Steroidal vs Nonsteroidal Topicals by Confocal Raman Microscopy (ISDS 2025) - "Hydrocortisone and crisaborole differentially modulate water, lipid organization, and protein structure across layers. These insights that can inform formulation design and mechanism-of-action studies."

Dual Biologic Therapy In Eosinophilic Esophagitis: A Case Report (ACAAI 2025) - "Despite treatment with dexlansoprazole, ranitidine, montelukast, cetirizine, budesonide (swallowed), and multiple food elimination diets, she experienced persistent retrosternal chest pain, dysphagia, abdominal pain, nausea and recurrent oral sores...After unsuccessful trials of crisaborole and cyclosporine, dupilumab was started...Discussion The 2025 American College of Gastroenterology guidelines support dupilumab use in EoE, however no recommendation exists for or against benralizumab use. This case highlights the potential role of dual biologic use, particularly in patients with severe EoE and coexisting atopic disease, though further research is needed."

Case report • Clinical • Allergic Rhinitis • Asthma • Contact Dermatitis • Dermatitis • Dermatology • Eosinophilic Esophagitis • Gastrointestinal Disorder • Immunology • Inflammation • Respiratory Diseases • IL13 • IL4 • IL5

Pfizer showcases leading skin disease treatments at CIIE (China Daily) - "The company's Inflammation & Immunology unit presented Cibinqo and Staquis for atopic dermatitis, along with Litfulo for alopecia areata."

Clinical data • Alopecia • Atopic Dermatitis

AI-Driven Comparative Efficacy of Topical Crisaborole versus Halometasone in Bilateral Hand for Vitiligo: A randomized and Non-Inferiority Study. (PubMed, J Am Acad Dermatol) - No abstract available

Head-to-Head • Journal • Dermatology • Immunology • Vitiligo

When The Usual Fails: Severe Eczema In A Syndromic Patient Resistant To Conventional Therapy (ACAAI 2025) - "We present a case of early-onset, treatment-refractory AD in a patient with RTS who demonstrated significant improvement following off-label use of dupilumab...She failed treatment with high-potency topical corticosteroids, crisaborole, and off-label tacrolimus, used in various combinations...The clinical response suggests that biologic therapy may be a safe and effective option for syndromic infants with recalcitrant eczema. This case also raises the possibility of immune dysregulation as a contributing feature in RTS."

Clinical • Atopic Dermatitis • CNS Disorders • Dermatology • Developmental Disorders • Fibrosis • Genetic Disorders • Immunology • Infectious Disease • Mental Retardation • Pruritus • Sleep Disorder

Allergic Contact Dermatitis Masquerading Recalcitrant Atopic Dermatitis: A Case Report (ISAD-RAJKA 2025) - "Despite complying with standard AD treatment including systemic therapy of cyclosporine, methotrexate, and occasional doses of prednisone, topical steroids and crisaborole, facial lesions thickened and pruritus worsened (SCORAD 10.9 to 39.85). ACD should be suspected in patients with recalcitrant AD, prompting comprehensive diagnostic examinations. Moreover, patch testing as the gold standard for diagnosing ACD should be considered to refine individualized, allergen-avoidant strategy to improve patient outcomes."

Case report • Clinical • Atopic Dermatitis • Contact Dermatitis • Dermatitis • Dermatology • Immunology • Pruritus

Allergy and dermatology US treatment guidelines review for adults with atopic dermatitis. (PubMed, J Allergy Clin Immunol Glob) - "We identified key similarities in the use of newer biologic agents, including dupilumab and tralokinumab. There are differences between the recommendations for topical phosphodiesterase-4 inhibitors, including crisaborole, and both topical and systemic Janus kinase inhibitors, including ruxolitinib, upadacitinib, abrocitinib, and baricitinib...Despite both sets of guidelines being evidence-based, variations in recommendations arise when factoring in patient preferences, perspectives, and risk aversion. As newer treatments become available for patients with AD, it will be important to monitor the evolving concordance or discordance of these guidelines given their direct impact on patient care."

Journal • Allergy • Asthma • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Pulmonary Disease • Respiratory Diseases

Seborrheic Dermatitis Revisited: Pathophysiology, Diagnosis, and Emerging Therapies-A Narrative Review. (PubMed, Biomedicines) - "However, new therapeutic approaches are under investigation, including PDE4 inhibitors (roflumilast, crisaborole, and apremilast), topical and oral JAK inhibitors, probiotics, and microbiome-targeted therapies. SD remains a challenging condition due to its relapsing course and limited long-term therapeutic options. Emerging therapies represent a valuable opportunity to address unmet clinical needs, particularly in patients with severe, recurrent, or treatment-resistant forms."

Journal • Review • Dermatitis • Dermatology • Immunology • Inflammation • Seborrheic Dermatitis

Topical Anti-Inflammatory Treatments for Atopic Dermatitis. (PubMed, JAMA Dermatol) - "Topical calcineurin inhibitors and crisaborole were associated with application-site irritation, and short-term topical steroid use was not associated with skin thinning. However, these findings were of low to moderate certainty, and longer-term data remain limited for many agents."

Journal • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

A Three-Component Path to Amino Thiadiazoles and Amino Oxadiazoles via a Nitrilium Ylide. (PubMed, J Org Chem) - "This strategy allows for the rapid, facile, and scalable assembly of numerous 2-amino-1,3,4-thiadiazoles and 2-amino-1,3,4-oxadiazoles using CDI as a C═O donor, without the requirement for cross-coupling methodologies. The limitations to the amine scope were explored, and the developed reaction was showcased by the strategic modification of a nonsteroidal anti-inflammatory drug (NSAID), crisaborole."

Journal

The evolving genetic landscape of ILVEN: A comprehensive review. (PubMed, J Eur Acad Dermatol Venereol) - "Somatic mutations in CARD14 activate NF-κB and IL-12/23/IL-17 signalling pathways and may be responsive to biologics such as secukinumab and ustekinumab...KRT10 mutations, which affect keratinocyte differentiation, show favourable responses to crisaborole and acitretin...The molecular characterization of ILVEN and related disorders supports a shift toward precision dermatology. As accessibility increases, genotype-directed therapy may replace empiric approaches with more targeted, effective and personalized management frameworks."

Journal • Review • Dermatology • Inflammation • Rare Diseases • ABCA1 • GJA1 • HRAS • IL12A • KRT10

TrumpRx unveiled with up to 85% discount on four Pfizer drugs (SeekingAlpha) - "The White House on Tuesday announced the launch of a direct-to-consumer website called TrumpRx, through which Pfizer (NYSE:PFE) has agreed to sell four of its prescription medicines, including its blockbuster arthritis drug Xeljanz, at up to an 85% discount. In addition to Xeljanz, which will be available at a 40% discount, the New York-based company has agreed to offer discounts ranging from 50% to 85% for its dermatitis drug Eucrisa, osteoporosis therapy Duavee, and migraine therapy Zavzpret."

Commercial • Ankylosing Spondylitis • Atopic Dermatitis • Idiopathic Arthritis • Migraine • Psoriatic Arthritis • Rheumatoid Arthritis • Ulcerative Colitis

Skin Allergy Research Society and Society for Eczema Studies Joint Task Force Guidelines of Care for Management of Atopic Dermatitis for Adult, Children and Special Population in India: An Evidence-Based Review and an Expert Consensus (EADV 2025) - "Key advancements include the introduction of topical crisaborole and JAK inhibitors for mild to moderate AD, along with a focus on emerging systemic therapies, such as biologics and systemic JAK inhibitors. In the Indian context, the guidelines define the roles of dupilumab and abrocitinib while also addressing the off- label use of tofacitinib and baricitinib in resource-limited settings... These guidelines align with global AD management while incorporating India-specific adaptations based on epidemiology, accessibility, and affordability. They serve as a key reference for dermatologists, pediatricians, and general practitioners in India and other resource-limited settings. Though tailored for India, they are also relevant to dermatologists in developing countries, guiding treatment selection based on disease patterns, environmental factors, and medication availability."

Clinical • Review • Allergy • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Pediatrics

Engineered Spider Silk in Core-Shell Multifunctional Fibrous Mat for Accelerated Chronic Diabetic Wound Healing via Macrophage Polarization. (PubMed, ACS Biomater Sci Eng) - "Here, a novel combination therapy of silk DOPA-crisaborole conjugate (SDC, angiogenic and anti-inflammatory) and eugenol (Eu, antioxidant) has been devised to promote chronic wound healing...In the diabetic rat model, the Dex-SDC/PCL-Eu fibers reduce inflammatory granulation tissue and ulceration, while promoting neovascularization, complete re-epithelialization, and well-organized dermis and epidermis formation with uniform collagen deposition. Thus, the developed multifunctional Dex-SDC/PCL-Eu fibrous mat accelerates full-thickness skin wound healing and holds promise for the treatment of chronic diabetic wounds."

Journal • IL10 • IL6

The use of Nemolizumab in refractory scrotal dysesthesias (EADV 2025) - "Materials & Two patients with a several year history of scrotal dysesthesia (pain and burning) that failed to improve with topical steroids, topical lidocaine, oral gabapentin, and patch testing were treated with Nemolizumab...Prior to starting Nemolizumab, patients 2 was taking oral indomethacin, oral gabapentin, and topical crisaborole to control his symptoms... Dysesthesias such as scrotodynia and vulvodynia are difficult to treat and cause tremendous morbidity to patients. Genital dysesthesias are heterogeneous, and they have a variety of underlying cause. In this series, Nemolizumab improved symptoms for two patients with scrotal dysesthesia that had been refractory to numerous topcial and oral agents."

Anesthesia • Atopic Dermatitis • CNS Disorders • Dermatitis • Dermatology • Immunology • Orthopedics • Pruritus • Psoriasis • Women's Health

Targeting Intracellular Pathways in Atopic Dermatitis with Small Molecule Therapeutics. (PubMed, Curr Issues Mol Biol) - "Although biologic agents such as dupilumab, tralokinumab, and lebrikizumab have revolutionized AD management, their high costs, injectable administration, and limited global accessibility highlight the need for alternative options...This review provides a comprehensive analysis of key agents including Janus kinase (JAK) inhibitors (upadacitinib, abrocitinib, baricitinib, ruxolitinib, delgocitinib), phosphodiesterase 4 (PDE4) inhibitors (crisaborole, difamilast, roflumilast, apremilast), as well as STAT6 degraders (KT621, NX3911), aryl hydrocarbon receptor modulators, histamine H4 receptor antagonists (adriforant, izuforant), and sphingosine-1-phosphate receptor modulators (etrasimod, BMS-986166). We summarize their mechanisms of action, pharmacological profiles, and pivotal clinical trial data, emphasizing their potential to address unmet therapeutic needs. Finally, we discuss safety concerns, long-term tolerability, and future directions for integrating small molecule..."

Journal • Review • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Inflammation • STAT6

Amorolfine hydrochloride cream and 2% crisaborole ointment: a study on their therapeutic benefits for keratotic tinea pedis. (PubMed, J Dermatolog Treat) - "The incidence of negative effects did not differ significantly between the two groups (p > 0.05). Conclusions For keratinized tinea foot, 2% crisaborole ointment can increase the effectiveness of amorolfine hydrochloride cream."

Journal • Dermatology • Pruritus

Use of PBPK modelling to extrapolate in vitro porcine ear skin permeability to in vivo human dermal absorption. (PubMed, Int J Pharm) - "In all cases, the stratum corneum:lipid vehicle Kp was identified as a key parameter for optimisation. The results demonstrated that, with appropriate model optimisation and incorporation of mechanistic parameters, in vitro data from porcine skin can enhance the accuracy in predicting in vivo human transdermal permeation of caffeine, crisaborole, and ketoprofen, and can be effectively used to simulate systemic exposure following topical application."

Journal • Preclinical

Crisaborole 2% Versus Tacrolimus 0.1% in Children With Mild to Moderate Atopic Dermatitis (clinicaltrials.gov) - P3 | N=66 | Not yet recruiting | Sponsor: Shalamar Institute of Health Sciences

New P3 trial • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

A systematic review of novel Phosphodiesterase-4 inhibitors in the treatment of psoriasis. (PubMed, Inflamm Res) - "PDE-4 inhibitors, both oral and topical, demonstrate promising efficacy and acceptable safety profiles in the treatment of psoriasis. To confirm their long-term benefits and improve clinical use, larger-scale studies with longer follow-up and a wider range of patients are required."

Journal • Review • Dermatology • Immunology • Psoriasis

Efficacy and Safety of Phosphodiesterase-4 Inhibitors in Vitiligo: A Systematic Review. (PubMed, Australas J Dermatol) - No abstract available

Journal • Dermatology • Immunology • Vitiligo

Microneedling Combined With Topical Crisaborole 2 % Ointment in Treatment of Vitiligo. (clinicaltrials.gov) - P=N/A | N=20 | Not yet recruiting | Sponsor: Tanta University

New trial • Dermatology • Immunology • Vitiligo

Structural Insights: What Makes Some PDE4 Inhibitors More Effective in Inflammatory Dermatoses. (PubMed, J Clin Aesthet Dermatol) - "PDE4, therefore, is a key drug target for alleviating inflammatory skin diseases. In this brief review, we discuss and simplify into clinically relevant terminology the molecular findings of a 2024 study by Wang et al, which analyzed the structural properties of dermatologic PDE4 inhibitors and thereby provided molecular rationale as to why roflumilast has the greatest potency and is highly efficacious across multiple inflammatory dermatoses."

Journal • Review • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Inflammation • Psoriasis • Seborrheic Dermatitis • IFNG • IL13 • IL22 • IL23A • IL4 • IL5 • TNFA